Syndax Pharmaceuticals Inc.

180 articles with Syndax Pharmaceuticals Inc.

• Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia

  1/30/2020

  - Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals' lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML

• Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook

  1/10/2020

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a strategic outlook for 2020 outlining key priorities for its broad pipeline.

• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.

• Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

  12/10/2019

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to commence a Phase 2 expansion cohort based on encouraging clinical activity and a well-tolerated safety profile observed to date in the ongoing Phase 1 dose escalation trial of SNDX-6352 in patients with chronic graft versus host disease (cGVHD).

• Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

  12/9/2019

  Data provide detailed look at potential underlying mechanism of action within cells

• 

  Clinical Catch-Up: November 4-8

  11/11/2019

  It was a busy week for clinical trial updates for the first week of November. Here’s a look.

• Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

  11/7/2019

  E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20

• Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias

  11/6/2019

  Syndax Pharmaceuticals, Inc. announced that the first patient has been dosed in AUGMENT-101, a Phase 1/2 clinical trial evaluating SNDX-5613, Syndax's potent, highly selective oral Menin inhibitor, in patients with relapsed/refractory acute leukemias.

• Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019

  10/31/2019

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 financial results on Thursday, November 7, after the close of the U.S. financial markets

• Syndax Announces Participation at Four Upcoming Investor Conferences - Aug. 28, 2019

  8/28/2019

  Syndax Pharmaceuticals, Inc. announced that members of the management team will participate in four upcoming investor conferences.

• Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update

  8/7/2019

   Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2019.

• Syndax to Participate in the BTIG Biotechnology Conference

  8/5/2019

  Syndax Pharmaceuticals, Inc. announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology therapies at the BTIG Biotechnology Conference on Monday, August 12, 2019 at 4:00 p.m. ET at the St. Regis New York.

• Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019

  7/31/2019

  Syndax Pharmaceuticals, Inc. announced that it will release its second quarter 2019 financial results on Wednesday, August 7, after the close of the U.S. financial markets.

• Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

  7/10/2019

  SNDX-5613 is a potent, highly selective, oral inhibitor of the interaction of Menin with the Mixed Lineage Leukemia (MLL) protein

• Syndax to Present at the JMP Securities Life Sciences Conference

  6/13/2019

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that Michael A. Metzger, President and Chief Operating Officer of Syndax, will present at the JMP Securities Life Sciences Conference on Thursday, June 20, 2019 at 10:00 a.m. ET at the St. Regis New York.

• Syndax to Present at the UBS Global Healthcare Conference

  5/14/2019

  Syndax Pharmaceuticals, Inc. announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 at 10:30 a.m. ET at the Grand Hyatt New York.

• Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

  5/6/2019

  E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19

• Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019

  4/29/2019

  Syndax Pharmaceuticals, Inc. announced that it will release its first quarter 2019 financial results on Monday, May 6, after the close of the U.S. financial markets.

• Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

  4/1/2019

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of updated findings from the melanoma and non-small cell lung cancer (NSCLC) cohorts of ENCORE 601,

• Syndax Announces $26.2 Million Offering of Common Stock and Warrants

  3/27/2019

  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it has entered into an agreement with Biotechnology Value Fund, L.P.